Beyond Meta, Cathie Wood’s ARKG Loads Up On These 4 Biotech Names
ARK Invest increased stakes in Ionis Pharmaceuticals (IONS), Veracyte (VCYT), Scribe Therapeutics (SCTX), and Beam Therapeutics (BEAM), while reducing exposure to 10x Genomics (TXG). The ETF bought shares worth millions in each biotech firm, with IONS, SCTX, and BEAM seeing pre-market gains, while VCYT declined. ARK also invested $37 million in Meta Platforms (META) across three ETFs, following a surge in Meta's shares.
How this was made
The 30-second read
Why it matters
The disclosed trades provide fresh insight into ARK's sector bets and may influence short‑term price dynamics.
Market read
Fund activity highlights sector preferences and could trigger trading interest in the listed biotech and tech stocks.
What to watch
Potential dilution from other investors and broader market volatility could offset fund impact.
Background
ARK Invest disclosed recent portfolio adjustments, adding biotech and cutting exposure to 10x Genomics.
Ticker impact
ARK Invest bought $37M of Meta shares across three ETFs, driving a pre‑market price rise.
Meta may see continued buying pressure in the next trading session.
Fund purchases are sizable and recent, indicating a bullish stance.
ARK purchased ~100,240 Ionis shares worth $4.5M following FDA approval of Zanvastro.
Expect modest upside as investors digest the approval and fund buying.
Combination of regulatory win and fund inflow provides a catalyst.
ARK added ~74,880 Veracyte shares (~$3M) after the company acquired Convergent Genomics.
Limited upside unless further acquisition synergies are highlighted.
Fund size modest and stock already down; impact may be muted.
ARK bought ~67,740 Scribe Therapeutics shares (~$1.9M) as the biotech prepares Phase 1 CRISPR data.
Potential short‑term rally if Phase 1 data release proceeds as expected.
Positive momentum and fund backing suggest near‑term interest.
ARK acquired ~102,560 Beam Therapeutics shares (~$2.6M) after Phase 1/2 data for BEAM‑302 were released.
Small upside possible, but recent price decline tempers expectations.
Mixed signals from data and price movement.
ARK sold ~31,600 shares of 10x Genomics (~$2.5M), reducing exposure.
Potential downside as fund exits may signal concerns.
Sell size modest; impact likely limited.
Market effects
Biotech sector may see modest uplift from ARK's visible confidence.
U.S. equity markets could experience slight positive bias in tech/biotech indices.
Limited to U.S. investors; no immediate global ripple.
Counterpoint
Fund buying may be premature if upcoming trial data disappoints.
Key entities
- PersonCathie Wood
Founder of ARK Invest, whose fund actions drive market attention.
- ETFARK Innovation ETF (ARKK)
One of the ETFs used to purchase Meta shares.
